Amarin last night reiterated that it believes Vascepa total net revenue, beyond 2020, will grow to reach “multiple billions of dollars.” The company explained, “The history of other therapies for chronic conditions suggests that growth builds over multiple years. At this time, the company is not providing guidance regarding annual revenue levels beyond 2020.”